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Abstract
Background Chronic kidney disease (CKD) patients experience skeletal muscle wasting and decreased exercise endurance.
Our previous study demonstrated that indoxyl sulfate (IS), a uremic toxin, accelerates skeletal muscle atrophy. The purpose
of this study was to examine the issue of whether IS causes mitochondria dysfunction and IS-targeted intervention using
AST-120, which inhibits IS accumulation, or mitochondria-targeted intervention using L-carnitine or teneligliptin, a dipeptidyl
peptidase-4 inhibitor which retains mitochondria function and alleviates skeletal muscle atrophy and muscle endurance in
chronic kidney disease mice.
Methods The in vitro effect of IS on mitochondrial status was evaluated using mouse myofibroblast cells (C2C12 cell). The
mice were divided into sham or 5/6-nephrectomized (CKD) mice group. Chronic kidney disease mice were also randomly
assigned to non-treatment group and AST-120, L-carnitine, or teneligliptin treatment groups.
Results In C2C12 cells, IS induced mitochondrial dysfunction by decreasing the expression of PGC-1α and inducing
autophagy in addition to decreasing mitochondrial membrane potential. Co-incubation with an anti-oxidant, ascorbic acid,
L-carnitine, or teneligliptine restored the values to their original state. In CKD mice, the body and skeletal muscle weights were
decreased compared with sham mice. Compared with sham mice, the expression of interleukin-6 and atrophy-related factors
such as myostatin and atrogin-1 was increased in the skeletal muscle of CKD mice, whereas muscular Akt phosphorylation was
decreased. In addition, a reduced exercise capacity was observed for the CKD mice, which was accompanied by a decreased
expression of muscular PCG-1α and increased muscular autophagy, as reflected by decreased mitochondria-rich type I fibres.
An AST-120 treatment significantly restored these changes including skeletal muscle weight observed in CKD mice to the sham
levels accompanied by a reduction in IS levels. An L-carnitine or teneligliptin treatment also restored them to the sham levels
without changing IS level.
Conclusions Our results indicate that IS induces mitochondrial dysfunction in skeletal muscle cells and provides a potential
therapeutic strategy such as IS-targeted and mitochondria-targeted interventions for treating CKD-induced muscle atrophy
and decreased exercise endurance.
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Introduction
Patients with chronic kidney disease (CKD) experience
skeletal muscle wasting and decreased exercise endurance.1
An impaired physical performance was observed from an
early stage of CKD.2 Physical inactivity derived from skeletal
muscle atrophy, referred to as sarcopenia, seriously
influences the prognosis of CKD patients because their
physical inactivity is correlated with renal prognosis and
mortality.3,4 Therefore, maintaining physical performance is
considered to be an essential factor for improving the
prognosis of CKD patients. However, robust evidence
regarding effective therapeutics for CKD-induced physical
inactivity is currently lacking.
So far, several molecular mechanisms have been proposed
to explain CKD-induced skeletal muscle atrophy.1,5 Oxidative
stress and inflammatory cytokines are thought to play an
important role in CKD-induced skeletal muscle atrophy and
decreasing of exercise capacity.1,6 In a recent study, using
indoxyl sulfate (IS)-loaded half-nephromized mice and a
mouse myofibroblast (C2C12) cell system, we reported that,
among the various uremic toxins, IS strongly induced skeletal
muscle atrophy by increasing the production of atrogin-1, a
member of the muscle specific ubiquitin ligase family, and
myostatin, a negative regulator of muscle growth, via inducing
muscular oxidative stress-mediated inflammation.7 In
addition, Nishikawa et al. also showed that IS might be
involved in a decrease in exercise capacity via inducing
muscular oxidative stress in CKD model mice and that IS
enhanced the production of reactive oxygen species (ROS) in
C2C12 cells.8 These findings suggest that IS has a critical role
in the development of CKD-induced skeletal muscle atrophy.
It is well known that exercise capacity is strongly related to
mitochondrial function in skeletal muscle. The amount of
mitochondria is regulated by both mitochondria biosynthesis
and its degradation.9,10 Tamaki et al. recently reported that
the amount of muscular mitochondria was decreased in the
early stage of CKD mice and that it was associated with
increased oxidative stress and inflammatory cytokines, such
as tumor necrosis factor (TNF)-α and interleukin (IL)-6.6 In
fact, oxidative stress and inflammation cause the expression
of the peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α), a master regulator for
mitochondrial biosynthesis, to be reduced and to an increase
in autophagy, a mitochondria degradation system.
Interestingly, Brault et al. demonstrated that the
overexpression of PGC-1α caused a resistance to muscle
atrophy that was induced by denervation or fasting.11
Similarly, Wenz et al. also showed that the overexpression
of PGC-1α in mice prevented muscle atrophy and hence
extended their life span.12 These findings led us to
hypothesize that IS causes mitochondria dysfunction in
skeletal muscle cells. If this is correct, therapeutic strategies
designed to inhibit IS accumulation or to retain muscular
mitochondria function would be effective for the prevention
and treatment of CKD-induced muscle atrophy.
The purpose of this study was to reveal whether (i) IS
causes mitochondrial dysfunction and (ii) whether IS- and
mitochondria-targeted therapeutics alleviate CKD-induced
muscle atrophy and the accompanying impaired exercise
endurance. AST-120, a charcoal absorbent, is used in IS-
targeted therapeutics, because it absorbs indole, a precursor
of IS, in the gut flora, resulting in a reduced level of IS
synthesis in the liver.13 For mitochondrial-targeted
therapeutics, we choose L-carnitine because it transports
free-fatty acids to mitochondria to maintain mitochondrial
function, and CKD patients are occasionally given L-carnitine
supplementation due to a L-carnitine deficiency. We also
used teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor
that can be safely administered to patients with reduced
renal function, because glucagon-like peptide-1 (GLP-1), a
major target of DPP-4, increased mitochondrial membrane
potential and oxygen consumption in addition to increasing
the expression of PGC-1α.14
Methods
Chemicals and materials
Indoxyl sulfate, dihydroethidium, and rabbit polyclonal anti-
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
antibody were purchased from Sigma-Aldrich (St Louis, MO).
Rabbit polyclonal anti-myostatin antibody was purchased
from proteintech (Chicago, USA). AST-120 was kindly provided
from Kureha Corporation (Tokyo, Japan). The antibiotic and
antimycotic mixture (10 000 U/mL penicillin, 10 000 μg/mL
streptomycin, 25 μg/mL amphotericin B), ascorbic acid was
purchased from Nacalai Tesque (Kyoto, Japan). Dulbecco’s
modified eagle medium and Dulbecco’s phosphate-buffered
saline (D-PBS) were purchased from Gibco (Invitrogen, Grand
Island, NY). L-carnitine was purchased from Otsuka
Phamaceutical Co., Ltd. (Tokyo, Japan). Teneligliptin was
generously provided from Mitsubishi Tanabe Pharma Co., Ltd.
(Osaka, Japan). All methods were carried out in accordance
with approved guidelines. All experimental protocols were
approved by Kumamoto University.
Cell culture
Mouse C2C12 myoblast cells were purchased from the RIKEN
Bioresource Center Cell Bank (Ibaraki, Japan). C2C12
myoblast cells were cultured in Dulbecco’s modified eagle
medium supplemented with 10% fetal bovine serum
(Hyclone Laboratories, Logan UT, USA), 100 U/mL penicillin,
100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B,
and maintained under 37°C and 5% CO2.
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Real-time reverse transcription polymerase chain
reaction (RT-PCR) analysis
Real-time RT-PCR analysis was performed as described in a
previous report.7 In a typical run, total RNA was extracted
using RNAiso PLUS (TaKaRa Bio Inc., Shiga, Japan) according
to the manufacturer’s protocol. The concentration and the
purity of the RNA extract were determined by the
absorbance at 260 and 280 nm. The cDNA was synthesized
using the PrimeScript® RT master mix (TaKaRa Bio Inc.).
Quantitative real-time RT-PCR analysis of PGC-1α,
myostatin, atrogin-1, and GAPDH was performed in an
iCycler thermal cycler (Bio-Rad) with an iQ5 qRT-PCR
detection system attached (Bio-Rad) using SYBR® Premix
Ex TaqII (TaKaRa Bio Inc.). Polymerase chain reaction
amplifications were performed under the following
conditions: 95°C for 3 min, for 40 cycles at 95°C for 10 s
(denaturation step), at 60°C for 1 min (annealing/extension
steps). The primers used are shown in Supporting
Information Table 1. The threshold cycle (Ct) values for each
gene amplification were normalized by subtracting the Ct
value calculated for GAPDH.
Mitochondrial staining
C2C12 myoblast cells were seeded at six well-plate sets with
flame sterilized-cover glasses and cultured overnight. After
cell adhesion, cells were starved for 2 h with serum free
medium and then treated with or without IS. The effect of
ascorbic acid, L-carnitine, or teneligliptin was determined
after a simultaneous treatment with IS. After a 3 h treatment,
the cells were washed with PBS and then incubated with
MitoRed (Dojin Chemical Co., Ltd, Kumamoto, Japan),
MitoGreen (Invitrogen, Grand Island, NY), and Hoechist33342
(Dojin chemical Co., Ltd, Kumamoto, Japan) in D-PBS for
20 min. After incubation, cells were washed with D-PBS and
observed by microscopy.
Animal experiments
All animal experiments were carried out in accordance with
the approved guidelines of Kumamoto University for the care
and use of laboratory animals. All animal experiments and
procedures were approved by Kumamoto University. sea:ICR
mice (5 weeks, male) were purchased from Kudo Co., Ltd
(Saga, Japan) and bred on a 12 h day/night cycle. 5/6-
nephrectomized model mice were produced in a two-step
surgery procedure according to previous reports.15 In brief,
two-thirds of the right kidney was removed, and 1 week later,
the left kidney was removed. At 4 weeks after the final
surgery, the mice were randomized by blood urea nitrogen
(BUN) and body weight, and were assigned to AST-120
(charcoal oral absorbent, 8 w/w% in powder diet), L-carnitine
(560 mg/kg, drinking water), or teneligliptin (60 mg/kg,
drinking water) treatment groups. Sham-operated mice and
control mice (CKD-operated mice) received a normal diet
and water. At 24 weeks after the final surgery, treadmill
experiments were performed. At 4 weeks after the treadmill
experiment, the mice were sacrificed, and blood or skeletal
muscle tissue was collected.
Blood urea nitrogen and creatinine
The plasma levels for BUN and creatinine were measured by
a Fujidrychem7000 and drychem slide system (FUJIFILM,
Kanagawa, Japan) following the manufacturer’s protocol.
High-performance liquid chromatography (HPLC)
analysis
Indoxyl sulfate levels in the plasma and gastrocnemius were
measured by an HPLC method, as described previously.7,16
In brief, plasma or a gastrocnemius homogenate extracted
with radioimmunoprecipitation assay buffer containing
150 mM NaCl, 1% nonidet P-40, 10 mM Tris–HCl (pH 7.4),
Table 1 Renal function, body weight, and muscle weight profile for sham, 5/6-nephrectomized (CKD) and AST-120, L-carnitine, or teneligliptin-treated
CKD mice
CKD
Sham Control AST-120 Carnitine Teneligliptin
BUN (mg/dL) 21.1 ± 1.2 56.7 ± 9.4b 45.5 ± 6.0a 53.9 ± 9.4b 66.9 ± 12.8b
SCr (mg/dL) 0.2 ± 0.02 0.8 ± 0.31a 0.4 ± 0.13 1.4 ± 0.42a 1.0 ± 0.05b
Final BW (g) (at 28 weeks) 49.1 ± 2.7 39.3 ± 1.4a 44.2 ± 0.5 45.4 ± 1.4 43.4 ± 0.9
Tibialis anterior (mg) 74.6 ± 3.3 70.0 ± 2.6 71.5 ± 1.7 74.0 ± 2.7 75.0 ± 3.7
Soleus (mg) 12.5 ± 0.6 10.3 ± 0.3a 10.7 ± 0.6 11.5 ± 0.5 11.3 ± 0.4
Gastrocnemius (mg) 216.0 ± 6.6 188.9 ± 9.1a 212.0 ± 5.5 211.0 ± 6.2 207.6 ± 6.2
Data are expressed as the mean ± standard error of the mean.
ap < 0.05.
bp < 0.01 compared with sham.
CKD, chronic kidney disease; BUN, blood urea nitrogen; SCr, serum creatinine; BW, body weight.
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and 1% protease inhibitor cocktail (Nacalai Tesque, Kyoto,
Japan) was mixed with acetonitrile (1:9, v/v for the plasma
sample or 1:3, v/v for the tissue homogenate sample) and
centrifuged at 12 000 g for 10 min. The supernatant was
collected and mixed with ultrapure water (1:1, v/v for a
plasma sample or 3:2, v/v for a tissue homogenate sample).
The sample was loaded to HPLC with 20 μL for the plasma
sample and 50 μL for the tissue homogenate. The HPLC
system consisted of an Agilent 1100 series intelligent pump
and a fluorescence spectrophotometer. A LiChro-sorb RP-18
column (Cica Merk, Tokyo, Japan) was used as the stationary
phase. The mobile phase consisted of 0.2 M acetate buffer
(pH 4.0)–acetonitrile (3:1, v/v) for IS. The flow rate was
1.0 mL/min. Indoxyl sulfate was detected by means of a
fluorescence monitor with excitation/emission wavelengths
set to 280 and 375 nm, respectively.
Western blotting analysis
Western blotting analysis was performed as described in a
previous report.7 Total protein was extracted with
radioimmunoprecipitation assay buffer containing 150 mM
NaCl, 1% nonidet P-40, 10 mM Tris–HCl (pH 7.4), 1% protease
inhibitor cocktail, and 1% phosphatase inhibitor cocktail
(Nacalai Tesque, Kyoto, Japan). A 30 μg sample of protein
was mixed with sample buffer containing 50 mM
dithiothreitol, heated 100°C, and separated by 10% sodium
dodecyl sulfate–poly-acrylamide gel electrophoresis. Proteins
were transferred to a polyvinylidene fluoride membrane and
then immunoblotted with antibodies against myostatin (Cell
Signaling Technology, MA, USA), Akt (Cell Signaling
Technology, MA, USA), p-Akt (Cell Signaling Technology, MA,
USA), and LC3 (Sigma-Aldrich, St. Louis, MO) under the room
temperature for 1 h. The sample was then immunoblotted
with horseradish peroxidase conjugated secondary antibody
at room temperature for 1 h. The intensity of each band
was detected using LAS4000mini (GE Healthcare, UK Ltd,
Backinghamshire, England) and quantified using ImageJ
software. The densitometric intensity was normalized with
GAPDH expression.
Enzyme-linked immunosorbent assay (ELISA)
Interleukin-6 and TNF-α in gastrocnemius were measured
using ELISA MAX™ Deluxe set (Biolegend, San Diego, USA)
following the manufacturer’s protocol.
Treadmill experiments
The running distance for the mice was measured using a
treadmill (MK-680S, Muromachi kikai, Tokyo, Japan), in
accordance with a previous report.9 At 3 days before the
experiment, we acclimated the mice to a motor-driven
treadmill at 14 m/min and a 0% incline. Mice were forced
to run until they were exhausted (they remained on the
electrical shocker plate). Electrical stimulation was set at
the recommended intensity described in the instructions.
The detailed treadmill conditions are described in Supporting
Information Table S2.
Succinate dehydrogenase (SDH) stain
Succinate dehydrogenase staining was performed as
described in previous reports.17,18 In brief, 10 μm thick of
frozen sections of skeletal muscle was dried by a dryer at
room temperature for 30 min. Tissue sections were reacted
with reaction solution (100 mM phosphate buffer, 1.5 mM
nitroblue tetrazolium, 48 mM disodium succinate) for
45 min at 37°C. After the reaction, the sections were washed
3 times with ion-exchanged water and mounted with mount-
quick aqueous (Daido Sangyo Co., Ltd, Saitama, Japan). The
resulting sections were observed by microscopy (Keyence,
BZ-9000 microscope, Osaka, Japan).
Statistical analyses
The means for the two groups of data were compared by the
unpaired t-test. The means for the groups were compared by
analysis of variance followed by Tukey’s multiple comparison.
A probability value of P < 0.05 was considered to be
significant.
Results
The effect of indoxyl sulfate on mitochondria and
the effect of anti-oxidant, L-carnitine, and
teneligliptin on indoxyl sulfate-induced
mitochondrial dysfunction in C2C12 cells
We investigated the effect of IS on mitochondrial
biosynthesis- or degradation-related factors such as PGC-1α,
a master regulator for mitochondrial biosynthesis or
autophagy (LC3II/LC3I ratio), one of the key systems for
mitochondrial degradation, using C2C12 cells. As shown in
Figure 1A, IS significantly decreased the mRNA expression
of PGC-1α and increased the ratio of LC3II/LC3I. Moreover,
MitoRed staining clearly indicated that incubation with IS
for 3 h caused a decrease in mitochondrial membrane
potential in C2C12 cells compared with untreated controls,
while IS had no effect on the amount of mitochondria, as
evidenced by MitoGreen staining.
Co-incubation with ascorbic acid, an anti-oxidant, restored
the IS-induced decrease in mitochondrial membrane
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Figure 1 Effect of indoxyl sulfate on peroxisome proliferator-activated receptor gamma coactivator 1-alpha expression, autophagy, or mitochondrial
membrane potential, and the effect of anti-oxidant, L-carnitine, and teneligliptin on indoxyl sulfate-induced mitochondrial dysfunction in C2C12 cells.
(A) mRNA expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha at 3 h after a 1 mM indoxyl sulfate treatment was
determined by real-time reverse transcription polymerase chain reaction. (B) Protein expression of LC3II/LC3I at 3 h after 1 mM indoxyl sulfate
treatment was determined by western blot. (C) Mitochondrial membrane potential was determined by MitoRed staining (the interaction of MitoRed
with mitochondria depends of the membrane potential of the mitochondria) and MitoGreen staining (MitoGreen appears to localize to mitochondria
regardless of mitochondrial membrane potential), the mitochondria selective fluorescent probe at 3 h after a 1 mM indoxyl sulfate treatment. Effect of
ascorbic acid (an anti-oxidant, 200 μμ; AsA), L-carnitine (5 mM; Car), or teneligliptin (1 μM; Tnl) on indoxyl sulfate-induced mitochondrial decline of
membrane potential at 3 h after 1 mM indoxyl sulfate treatment. AsA, Car, or Tnl was co-incubated with indoxyl sulfate. Data are expressed the
mean ± standard error of the mean (n = 3–4). *p < 0.05 compared with control.
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potential, suggesting the importance of oxidative stress in IS-
induced mitochondrial dysfunction (Figure 1C). Similar to
ascorbic acid, L-carnitine or teneligliptine also inhibited the
development of impaired mitochondrial functions in the
presence of IS.
The effect of AST-120, L-carnitine, and teneligliptin
on chronic kidney disease-induced muscle atrophy
using 5/6-nephrectomized mice
To confirm the findings obtained using C2C12 cells, we
examined the effect of therapeutic intervention on
CKD-induced muscle atrophy and muscle endurance using
5/6-nephrectomized mice. The experimental scheme
for evaluating the 24 week administration of AST-120,
L-carnitine, and teneligliptin to CKD mice is shown in Figure 2.
Blood urea nitrogen (BUN) and serum creatinine levels in the
CKD mice (control) were significantly increased compared
with those in sham (healthy) mice (Table 1). However, no
significant differences in renal function were observed
between the CKD groups used in this study (Table 1),
indicating that the therapeutic effect of each intervention
was not due to an amelioration of the renal function. The
body weights of the CKD mice were significantly decreased
as compared with that of sham mice, while this reduction
was suppressed by the administration of AST-120, L-carnitine,
or teneligliptin (Table 1). We also measured the weights of
skeletal muscle of the mice. As a result, the weights of
soleus and gastrocnemius were significantly decreased in
CKD mice as compared with those of sham mice. Similar
to body weight, these muscular weight changes were
suppressed by treatment with AST-120, L-carnitine, or
teneligliptin (Table 1). There were no significant changes
in the weight of the tibialis anterior among the groups.
The effect of AST-120, L-carnitine, and teneligliptin
on plasma and muscular indoxyl sulfate levels in
chronic kidney disease mice
To clarify whether AST-120, L-carnitine, and teneligliptin
influence the accumulation of IS, the IS levels in plasma and
skeletal muscle (gastrocnemius) of CKD mice were measured.
As shown in Figure 3A, the plasma concentration of IS in the
CKD mice was eight-fold higher than that of sham mice
(4.7 ± 0.4 μM for sham mice; 39.2 ± 7.7 μM for CKD mice).
As expected, the elevated IS level in plasma was decreased
to the levels of the sham mice by the administration of AST-
120 (6.4 ± 0.6 μM for CKD + AST mice). In contrast, L-carnitine
or teneligliptin had no effect on plasma IS levels in CKD mice.
We also measured IS levels in skeletal muscle (gastrocnemius)
(Figure 3B). The IS level in skeletal muscle was increased by
three-fold in the case of the CKD mice compared with the
sham mice. Similar to the changes in the plasma IS level, IS
levels in skeletal muscle were significantly reduced by AST-
120, while the administration of L-carnitine or teneligliptin
had no effect on the IS levels in muscles of CKD mice
(13.4 ± 1.2 pmol/mg protein for sham mice; 38.3 ± 6.0 pmol/
mg protein for CKD mice; 13.9 ± 1.5 pmol/mg protein for
CKD + AST-120; 35.9 ± 5.5 pmol/mg protein for CKD + Car;
39.6 ± 8.5 pmol/mg protein for CKD + Tnl) (Figure 3B).
The effect of AST-120, L-carnitine, and teneligliptin
on the expression of inflammatory cytokines in
chronic kidney disease mice
We previously reported that the expression of inflammatory
cytokine genes is increased in skeletal muscles of IS-loaded
half-nephromized mice.7 Here, we evaluated the effect of
Figure 2 Experimental scheme for evaluating AST-120, L-carnitine, and teneligliptin on chronic kidney disease mice. sea:ICR mice (♂, 5 weeks) were
used in the experiment. 5/6-nephrectomized mice (chronic kidney disease mice) were produced in two-step surgery according to the previous reports
[Miyamoto. KI. 2013]. At 4 weeks after final surgery, mice were randomized by blood urea nitrogen and body weight, and were assigned to AST-120
(oral charcoal absorbent, 8 w/w% in powder diet), L-carnitine (560 mg/kg, drinking water), or teneligliptin (60 mg/kg, drinking water)-treated group.
Sham-operated mice and control mice (chronic kidney disease-operated mice) were received normal diet and water. At the 24 weeks after the final
surgery, treadmill experiment was performed. Four weeks after treadmill experiment, mice were sacrificed, and blood or skeletal muscle tissue was
collected.
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AST-120, L-carnitine, and teneligliptin on the expression of
inflammatory cytokines in CKD mice. As shown in Figure 4A,
the IL-6 levels in skeletal muscle (gastrocnemius) were
significantly increased in the CKD mice. This increase tended
to be suppressed by the AST-120 treatment (Figure 4A). The
same tendency was also observed in the case of TNF-α levels
(Figure 4B). On the other hand, the administration of
L-carnitine and teneligliptin had no effect on IL-6 and TNF-α
levels in skeletal muscle.
The effect of AST-120, L-carnitine, and teneligliptin
on the expression of myostatin, atrogin-1, and Akt
phosphorylation in chronic kidney disease mice
We next evaluated the expression of muscle atrophy-related
genes such as myostatin and atrogin-1 in the gastrocnemius
of CKD mice. Both the expression of mRNA and the
corresponding protein, myostatin, were increased in the CKD
mice (Figure 5A and B). Similarly, the mRNA expression of
atrogin-1 was also increased in the CKD mice (Figure 5C). Such
inductions of myostatin and atrogin-1 expression in CKD mice
were significantly inhibited by the administration of AST-120,
L-carnitine, and teneligliptin (Figure 5A–C). On the other hand,
the Akt phosphorylation level in the gastrocnemius was
significantly decreased in CKD mice but was recovered by the
administration of AST-120, L-carnitine, and teneligliptin
(Figure 5D).
The effect of AST-120, L-carnitine, and teneligliptin
on exercise capacity in chronic kidney disease mice
Because the capacity of CKD mice for exercise is known to be
decreased in the early stages of CKD, we evaluated the effect
of AST-120, L-carnitine, and teneligliptin on the exercise
capacity (running distance) of CKD mice. As expected, the
exercise capacity in CKD mice was lower than that of the
sham mice. Interestingly, the administration of AST-120,
L-carnitine, and teneligliptin significantly suppressed this
impaired exercise capacity, i.e. exercise capacity was
increased (Figure 6A).
Previous reports and our in vitro experiments (Figure 1)
demonstrated that there is mutual relationship between
exercise capacity in treadmill experiments and muscular
mitochondrial function.6,9,10,19 We therefore further
Figure 3 Plasma and skeletal muscle concentration of indoxyl sulfate in chronic kidney disease and AST-120 (AST), L-carnitine (Car), or teneligliptin
(Tnl)-treated chronic kidney disease mice. The concentration of indoxyl sulfate in (A) plasma and (B) gastrocnemius was determined by high-
performance liquid chromatography. Data are expressed the mean ± standard error of the mean (n = 5–9). **p < 0.01 compared with sham.
##
p < 0.01 compared with chronic kidney disease.
Figure 4 Effect of AST-120 (AST), L-carnitine (Car), or teneligliptin (Tnl) on protein expression of interleukin-6 and tumor necrosis factor-α in skeletal
muscle of chronic kidney disease mice. (A) Interleukin-6 and (B) tumor necrosis factor-α expression in gastrocnemius were determined by enzyme-
linked immunosorbent assay. Data are expressed the means ± standard error of the mean (n = 5–9). *p < 0.05 compared with sham.
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evaluated the mitochondrial status in skeletal muscle of CKD
mice. The mRNA expression of PGC-1α in the gastrocnemius
was significantly decreased in CKD mice (Figure 6B), while
the administration of AST-120, L-carnitine, and teneligliptin
restored the change of PGC-1α expression (Figure 6B). We
also evaluated whether autophagy was induced in the
gastrocnemius of the CKD mice. As shown in Figure 6C, the
LC3II/LC3I ratio was significantly increased in the CKD mice,
suggesting that autophagy was induced. The changes in the
LC3II/LC3I ratio were inhibited by the administration of AST-
120, L-carnitine, and teneligliptin (Figure 6C).
Muscle fibre distribution is altered by certain disease
conditions due to the induction of fibre transition from
type I fibres to type II fibres.20–22 The resulting reduced
type I fibre content is associated with mitochondrial
dysfunction, because type I fibres are mitochondria-rich,
slow twitch fibres. Therefore, we further investigated the
muscle fibre distribution by SDH staining. This method
utilizes the activity of SDH, a mitochondrial respiratory
chain enzyme, to determine the myofibre type.18,21 As
shown in Figure 6D, the number of type I fibres was
decreased in CKD mice, whereas these alterations were
Figure 5 Effect of AST-120 (AST), L-carnitine (Car), or teneligliptin (Tnl) on myostatin, atrogin-1 expression, and Akt phosphorylation in skeletal muscle
of chronic kidney disease mice. (A) mRNA and (B) protein expressions of myostatin in gastrocnemius were determined by real-time reverse
transcription polymerase chain reaction and western blots. mRNA expression of (C) atrogin-1 expression in the gastrocnemius was determined by
real-time reverse transcription polymerase chain reaction. (D) Akt phosphorylation in the gastrocnemius was determined by western blots. Relative
intensity of pAkt/Akt was quantified using the ImageJ software. Data are expressed as the mean ± standard error of the mean (n = 4–9). *p < 0.05,
**




p < 0.01 compared with chronic kidney disease.
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Figure 6 Effect of AST-120 (AST), L-carnitine (Car), or teneligliptin (Tnl) on mice exercise capacity, peroxisome proliferator-activated receptor gamma
coactivator 1-alpha expression, autophagy, and skeletal muscle fibre type in chronic kidney disease mice. (A) Mice exercise capacity was determined
treadmill experiment. (B) mRNA expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha in gastrocnemius was
determined by real-time reverse transcription polymerase chain reaction. (C) Protein expression of LC3II/LC3I in gastrocnemius was determined by
western blot. (D) Succinate dehydrogenase staining of soleus muscle was determined by succinate dehydrogenase staining. Data are expressed the
mean ± standard error of the mean (n = 4–9). *p < 0.05, **p < 0.01 compared with control. #p < 0.05, ##p < 0.01 compared with chronic kidney
disease.
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inhibited by the administration of AST-120, L-carnitine, and
teneligliptin.
Discussion
Impaired physical performance is not only correlated with a
renal prognosis and mortality but also constitutes an
independent cardiovascular risk in patients with CKD.2,4
However, evidence regarding a therapeutic strategy for
treating CKD-induced muscle atrophy is limited due to a lack
of information concerning the molecular mechanism
responsible. It is currently thought that the enhancement in
oxidative stress and inflammatory cytokines is closely
associated with CKD-induced muscle atrophy.1,23,24
Interestingly, feeding a high protein diet not only reduces
exercise endurance despite an increased muscle mass and
muscle power in CKD mice6 but also exacerbates impaired
renal function that is accompanied by an increased production
of uremic toxins.25 This body of experimental evidence led us
to hypothesize that uremic toxins play an important role in the
mutual relationship between the aggravation of renal
function, exercise capacity, and a high protein diet. In fact,
our previous study, showing that among uremic toxins, IS
strongly accelerates skeletal muscle atrophy via the induction
of oxidative stress-mediated inflammation using IS-loaded
half-nephromizedmice and a C2C12 cell system confirmed this
assumption.7 The present study further demonstrated that IS
also accelerates mitochondrial dysfunction via the induction
of oxidative stress. Based on these findings, we explored the
therapeutic impact of inhibiting the accumulation of IS and
mitochondrial dysfunction on CKD-induced muscle atrophy
and decreased muscle endurance, and the findings showed
that AST-120, L-carnitine, and teneligliptin function to
potentiate the prevention of CKD-induced physical inactivity
mainly via maintaining mitochondrial function, suppressing
atrogin-1/myostatin expression, and recovering Akt
phosphorylation in skeletal muscle.
It has been reported that a reduction in exercise capacitywas
observed even in an early stage of CKD.2,6 Recent studies
further indicated that such an impaired exercise capacity was
induced prior to the development of muscle atrophy, and this
was mainly caused by mitochondrial dysfunction in skeletal
muscle.6 Similar results were also reported for early stage of
CKD mice (16–20 weeks aged mice, 9–13 weeks after 5/6 Nx
operation), and their exercise capacities were decreased
accompanied by a reduction in mitochondrial function without
muscle atrophy. On the other hand, the late stage of CKD mice
(48 weeks aged mice, 41 weeks after 5/6 Nx operation) showed
a marked decrease in both body weight and skeletal muscle
weight with the impaired exercise capacity and mitochondrial
dysfunction. In this study, we used an intermediate stage of
CKD mice (34 weeks aged mice, 28 weeks after 5/6 Nx
operation), and their characteristics as compared with sham
mice were as follows1: The body weight and weights of the
soleus or gastrocnemius were significantly decreased in CKD
mice,2 plasma and muscular IS levels were significantly
increased in CKD mice,3 IL-6 and atrophy-related factors
(myostatin and atrogin-1) in skeletal muscle were increased
whereas muscular Akt phosphorylation was decreased in CKD
mice,4 and exercise capacity was decreased in CKD mice and
was accompanied by a reduction in muscular PCG-1α
expression and increased muscular autophagy as reflected by
a decrease in type I fibres (mitochondria rich fibres). These
features are well consistent with IS-loaded half-nephromized
mice as shown previously.7 The administration of AST-120 to
the CKD mice significantly decreased the plasma and muscular
IS levels and, hence, restored exercise capacity, muscle weight,
and the number of type I slow twitch fibres and suppressed
mitochondrial dysfunction. These findings further support the
conclusion that IS is one of the humoral factors responsible
for muscle atrophy in CKD.
Increased oxidative stress and inflammatory cytokines
decrease mitochondria function.6 The present study revealed
that IS decreases the expression of PGC-1α (mitochondrial
biosynthesis-related factor) and increases autophagy
(mitochondrial degradation-related factor) in skeletal muscle
in both in vivo and in vitro experiments. Interestingly, IS
reduced membrane potential in C2C12 cells, and these events
were markedly ameliorated by the treatment of an anti-
oxidant, ascorbic acid. Therefore, IS-induced intracellular
ROS production contributes to the induction of mitochondria
dysfunction observed in CKD conditions. We previously
proposed a mechanism for the IS-induced production of ROS
in skeletal muscle cells in which IS, which accumulates
intracellularly via organic anion transporters, results in
increased ROS production by the activation of NADPH oxidase
and the aryl hydrocarbon receptor. Such enhanced ROS
production might be involved in the IS-induced mitochondria
dysfunction reported herein. Further experiments will clearly
be needed to clarify the molecular mechanism responsible
for IS-induced mitochondria dysfunction.
In CKD patients, a restriction of protein intake, a decrease
in L-carnitine biosynthesis, and the easy removal of
L-carnitine by dialysis cause a L-carnitine deficiency. Such a
L-carnitine deficiency results in a decline in muscle power,
fatigue, non-ketotic hypoglycemia, or myocardial myopathy,
while L-carnitine supplementation is effective for myopathy
or for a decrease in muscle mass and power in elderly
people.26,27 The findings reported herein indicate that an
L-carnitine treatment ameliorates the muscle atrophy and
exercise capacity in CKD mice without affecting their renal
function or the IS levels in both plasma and muscle. This
could be due to the inhibition of mitochondrial dysfunction
and decreased numbers of type I slow twitch fibres. Several
reports have indicated that the L-carnitine can exert a
pleiotropic effect. For example, the administration of L-
carnitine to exercise-loaded mice increased their exercise
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endurance via the up-regulation of mitochondrial
biosynthesis factors such as PGC-1α.28 L-carnitine also
decreased the levels of markers for oxidative stress, such as
8-OHdG and 4-hydroxynonenal and TNF-α in livers of
non-alcoholic steatohepatitis model mice,29 suggesting that
L-carnitine exhibits anti-oxidative and anti-inflammatory
actions. In mice that are fed a high-fructose diet which is
known as an acquired model of insulin resistance, the
presence of L-carnitine reduced protein oxidation in the lens,
and the decreased anti-oxidative enzymes were recovered,
thus preserving mitochondrial function.30 Moreover, the
presence of L-carnitine increases Akt phosphorylation and
accelerates myotube formation in C2C12 cells31 and in the
muscle of rats.32 These pleiotropic effects of L-carnitine,
including anti-oxidative and anti-inflammatory activities and
maintaining Akt signaling, could play an important role in
the protection of mitochondrial function in CKD conditions,
especially in cases of higher IS accumulation, such as uremia.
However, recently, Koeth et al. reported that metabolism by
intestinal microbiota of dietary L-carnitine produces
trimethylamine-N-oxide (TMAO) and accelerates
atherosclerosis in mice.33 In addition, they also showed that
higher TMAO level predicted increase risks for prevalent
cardiovascular disease and incident adverse cardiac events.
On the other hand, other reports demonstrated that oral
L-carnitine supplementation increases TMAO but reduces
markers of vascular injury in hemodialysis patients34 or
L-carnitine intake and high TMAO plasma levels correlate
with low aortic lesions.35 Therefore, the link between gut
microbiota metabolism of L-carnitine and cardiovascular
disease risk has generated much debate over the utility of
supplemental intake of L-carnitine.
We also found, for the first time, that teneligliptin has a
therapeutic potential against CKD-induced muscular
dysfunction without causing changes in IS accumulation. A
DPP-4 inhibitor is used for treating patients with type 2
diabetes. The main mechanism for its anti-diabetic effect is
to inhibit DPP-4, a degradative enzyme of incretin hormones
such as GLP-1 and glucose-dependent insulinotropic
polypeptide.36 Incretin has been known to exert pleiotropic
effects on the central nervous system, the liver,
cardiovascular, lung, kidney, or skeletal muscle. Kang et al.
recently reported that GLP-1 increased the mitochondrial
membrane potential and oxygen consumption in addition to
increasing of PGC-1α expression.14 Thus, DPP-4 inhibitors also
exert pleiotropic effects via their ability to enhance the action
of GLP-1.37 In fact, Fukuda-Tsuru et al. reported that a
teneligliptin treatment suppressed mitochondrial dysfunction
and lipid accumulation in livers in mice that had been fed a
high-fat diet.38 It is well known that GLP-1 ameliorates insulin
resistance via the activation of the PI3K-Akt signal pathway in
skeletal muscle.39 In addition, Kimura et al. reported that
teneligliptin acts as a hydroxyl radical scavenger.40 Wang
et al., using human proximal tubular cells, also reported that
diportin, another DPP-4 inhibitor, inhibited cell injury via the
inhibition of IS-induced NF-κB signaling, ROS/p38MAPK/ERK,
and recovering the PI3K-Akt signaling pathway without
involving the action of GLP-1. This suggests that DPP-4
inhibitors could have a direct cytoprotective function as
well.41 Taking these findings into consideration, it would
appear that teneligliptin may exert cytoprotective activities
not only via GLP-1 indirectly but also its direct action against
CKD-induced muscle atrophy.
In clinical settings, AST-120 is used to suppress the
progression of renal failure in CKD patients via inhibiting the
accumulation of uremic toxins. On the other hand,
L-carnitine injections are occasionally administered to CKD
patients, especially those who are receiving dialysis therapy
because of the high incident of complications with L-carnitine
deficiency. In the case of teneligliptin, it can be used safely in
diabetes patients with decreased renal function because it is
excreted via both liver and kidney. Accordingly, AST-120,
L-carnitine, and teneligliptin can be used to treat CKD patients
with muscle atrophy and impaired muscle exercise endurance.
Although AST-120, L-carnitine, and teneligliptin exhibit anti-
muscle atrophy actions, their mechanisms are different from
each other. Thus, it may be expected that a combination of
AST-120 and L-carnitine or AST-120 and teneligliptin therapy
or a combination of all may exert an additive or synergic effect
against CKD-induced muscle dysfunction.
In this in vitro study, C2C12 cells were incubated with 1 mM
IS for 3 h in the absence of albumin, which is the highest
individual total plasma IS concentration ever reported.42 It is
important to consider the concentration of free uremic toxins
on their biological activity, which means that the experiments
need to be conducted using the correct albumin concentrations
or with the correct free concentration. Vanholder et al.
previously pointed out that the use of unrealistically high free
concentrations of uremic toxins compared with the
concentrations observed in human CKD and/or inappropriately
low albumin concentrations may blur the interpretation of the
biochemical effects of uremic toxins.43 On this point, the IS
concentration used in this cell culture study may have been
unusually high and the free concentration irrelevant. On the
other hand, in clinical situations, uremic patients are routinely
exposed to pathological IS concentrations for long periods of
time (for many years). In the cell culture study, however, the
cells were exposed to a high IS concentration only for several
hours. High concentrations in in vitro experiments with s short
exposure (~several hours) have been used in a number of
previous studies, where the short exposure might compensate
for the high concentration, in contrast to actual exposure
periods, where uremic toxins would have more time to reach
the intracellular compartments and to exert their biological
activity.
Our experiments using mice are not necessarily equivalent
to the human condition, and other presumed or unexpected
actions of IS, AST-120, L-carnitine, and teneligliptin may
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contribute to the results on this study. Recently, Sato et al.
also demonstrated that IS potentiated mitochondrial
dysfunction as well as our study. In addition, a significant
inverse association between plasma IS levels and skeletal
muscle mass in patients with CKD was observed.44 The data
suggest that IS is a pathogenic factor for muscle atrophy in
the patients with CKD. However, the clinical data reported
by Sato et al. were a correlation study and, as a result, would
not have the same relevance as would be obtained in a large
randomized study. In addition, correlating the concentration
of IS with muscular atrophy cannot be considered to be
proof of causation. Here, IS can be considered only as a
marker of kidney failure, and there is a plethora of other
retained compounds that could have played a role in this
process, either directly or indirectly. Further clinical
randomized studies will be needed to clarify whether IS is
solely a marker of renal function or a pathogenic factor
related to muscle atrophy and to confirm the anti-muscle
atrophy action of the above interventions in CKD patients
in the future.
Conclusions
Together with our previous report,7 we demonstrated the
existence of a mutual relationship between IS and skeletal
muscle atrophy/exercise endurance in CKD conditions.
Additionally, IS was found to induce mitochondrial
dysfunction via increasing oxidative stress. Based on these
molecular mechanisms, we provide two therapeutic
strategies that are IS-targeted (AST-120) and mitochondria-
targeted (L-carnitine and teneligliptin) interventions for
CKD-induced muscle atrophy and decreased exercise
endurance. Thus, this study provides new beneficial
evidence for IS- and mitochondria-targeted intervention
against CKD-induced muscle atrophy and decreased exercise
endurance.
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